CSI Market
Sign In | Register

Applied Genetic Technologies (AGTC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AGTC Annual Cash Flow →
Examining cash flow movements between Applied Genetic Technologies and Sep 30 2021 reveals how Sep 30 2022 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2022)
3 Months 		(Jun 30 2022) (Mar 31 2022) (Dec 31 2021) (Sep 30 2021)
Operating Activities
Income-18.41
Depreciation & amortization0.37
Amortization of Other Assets0.16
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.65
Income (Loss) from Equity Method Investments0.08
Fair Value Adjustment of Warrants0.19
Conversion Of Preferred Stock Warrant To Common Stock Warrant-
Capital Lease Obligations Incurred-
Lease Incentive Obligation Related To Purchase Of Leasehold Improvements-
Noncash Lease Expense-
Noncash Interest On Lease Liabilities-
Increase Decrease In Operating Lease Right Of Use Asset-
Collaboration Revenue From Equity Investments In Affiliate-
Operating Lease Right Of Use Asset Amortization Expense0.15
Expense For Shares Of Common Stock Issued To A Vendor0.00
Increase Decrease In Operating Lease Liability-0.25
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Accounts Payable0.46
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.05
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.51
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-16.04
Investing Activities
Capital Expenditures-0.30
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Cost Method Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Assets, Investing Activities0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.30
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-2.24
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock9.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Taxes Related To Share Based Payment Arrangement-
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities7.14
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-16.34
Total Cash Flow-9.20
4 historic quarters locked

Sign in to unlock the full Applied Genetic Technologies cash flow history.

Sign In Create Free Account

About Applied Genetic Technologies Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-22-289919

Figures are derived from filed reports and may be restated. Historical data is subject to revision.